| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Research and development (including $10,125,000 for the year ended December 31, 2025 and $2,801,435 for the six months ended December 31, 2024, from a related party) | $10.2M+258.5% | $2.9M-30.4% | $4.1M-60.7% | $10.5M | — | — |
| General and administrative | $2.8M+79.4% | $1.6M-51.0% | $3.2M+382.7% | $663K | — | — |
| Total operating expenses | $13.1M+195.1% | $4.4M-39.4% | $7.3M-34.2% | $11.1M | — | — |
| Loss from Operations | -$13.1M-195.1% | -$4.4M+39.4% | -$7.3M+34.2% | -$11.1M-608.1% | -$1.6M-530.0% | -$249K |
| Loss before income taxes | -$13.1M-195.1% | -$4.4M+39.4% | -$7.3M+34.2% | -$11.1M-1114.1% | -$915K-269.6% | -$248K |
| Income tax provision | -$838-1230.2% | -$63+96.1% | -$2K | — | -$81K | $0 |
| Net loss | -$13.1M-195.1% | -$4.4M+39.5% | -$7.3M+34.2% | -$11.1M-1015.8% | -$996K-302.1% | -$248K |
| Net loss applicable to common stock per share, basic (in Dollars per share) | -$0.35-191.7% | -$0.12+55.6% | -$0.27+99.3% | -$36.35-16422.7% | -$0.22+85.5% | -$1.52 |
| Net loss applicable to common stock per share, diluted (in Dollars per share) | -$0.35-191.7% | -$0.12 | — | — | -$0.22+85.5% | -$1.52 |
| Weighted average common stock outstanding, basic (in Shares) | 36.8M+0.8% | 36.5M+34.7% | 27.1M+8764.8% | 306K-78.5% | 1.4M+20.4% | 1.2M |
| Weighted average common stock outstanding, diluted (in Shares) | 36.8M+0.8% | 36.5M | — | — | 1.4M+20.4% | 1.2M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.